Dr. Gregory Robinson is Chief Scientific Officer at Tevard Bio, a biotechnology company pioneering tRNA-based therapies for a broad range of genetic diseases. Dr. Robinson has more than 30 years of experience helping advance scientific discoveries into the clinic, including more than a decade developing gene therapies using adeno-associated virus (AAV) vectors and non-viral approaches to target different tissues for a variety of diseases. Before joining Tevard, Dr. Robinson held CSO roles at several gene therapy companies including Summation Bio, a non-viral approach to treating ophthalmologic disorders; Akouos, developing treatments for hearing disorders (acquired by Lilly); Nightstar Therapeutics, targeting inherited retinal diseases (acquired by Biogen); and Agilis, focused on rare central nervous system disorders (acquired by PTC Therapeutics). Prior to his experience in gene therapy, Dr. Robinson held leadership roles at Shire Plc. and Eyetech Pharmaceuticals. He has co-authored more than 40 peer-reviewed publications and has 13 issued patents. Dr. Robinson holds a Ph.D. in Biochemistry from Boston University, completed postdoctoral studies at the Dana Farber Cancer Institute, Harvard Medical School, and received his B.S. in Biology from Macalester College.

Stay In

The Know

Blank Form (#3)